Seaport Res Ptn Has Positive Outlook of HIMS FY2024 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Research analysts at Seaport Res Ptn upped their FY2024 earnings per share estimates for Hims & Hers Health in a report released on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will earn $0.25 per share for the year, up from their previous forecast of $0.23. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2025 earnings at $0.51 EPS.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.04) earnings per share.

HIMS has been the topic of several other reports. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. TD Cowen raised their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, Truist Financial lifted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $23.44 on Thursday. The firm has a market capitalization of $5.03 billion, a P/E ratio of 53.27 and a beta of 1.06. The business has a 50 day simple moving average of $18.22 and a 200 day simple moving average of $18.26. Hims & Hers Health has a 12-month low of $6.58 and a 12-month high of $25.74.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Quantbot Technologies LP increased its stake in Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after acquiring an additional 208,621 shares during the period. IvyRock Asset Management HK Ltd acquired a new position in shares of Hims & Hers Health in the first quarter valued at $433,000. Swiss National Bank lifted its position in Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after purchasing an additional 2,000 shares during the period. Sei Investments Co. boosted its stake in Hims & Hers Health by 206.9% during the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after buying an additional 37,890 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at $228,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the transaction, the insider now directly owns 169,935 shares in the company, valued at approximately $3,935,694.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $22.20, for a total value of $166,500.00. Following the sale, the insider now owns 193,980 shares in the company, valued at approximately $4,306,356. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 650,659 shares of company stock valued at $11,712,198 in the last quarter. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.